Europe White Biotech Market

Europe White Biotech Market Share (2024 to 2029)

Europe White Biotech Market is estimated to develop in the foreseen years with a reasonable CAGR of about 9% throughout the forecast period (2022 - 2027).

White biotechnology plays an essential role in reducing greenhouse gases, using fossil fuels and raw materials, leading to cleaner and greener industries. By sourcing raw materials from agriculture, white biotechnology can also contribute to a more competitive, globally-compliant, environmentally sustainable European agriculture. White biotechnology has been used in industry for two decades as laundry detergent enzymes; it has also been used to make penicillin and an alternative to animal insulin, as well as to produce many vaccines and medications.

The emergence of government initiatives to promote white biotechnology is one of the main drivers of demand in the European white biotechnology market. Also, white technology is also environmentally friendly and produces little waste by using efficient production methods. In addition, the growing need for various consumer industries, such as consumer goods and automotive, to meet sustainability goals is expected to increase demand for technology during the projected period. In addition to growth factors, increased government support for the growth of white biotechnology through R&D activities and programs is also expected to increase growth opportunities for the Europe white biotechnology market. Besides, the growing demand for green chemicals in developed regions that are willing to pay higher prices for renewable products will further accelerate demand in this market. The main challenge that could hinder the growth of the market for white biotech includes the deterioration of the fertility of agricultural land. This is due to excessive and inappropriate use of fertilizers on crops, which has resulted in decreased fertility of agricultural land. Due to the excessive use of fertilizers, the prices of organic crops fluctuated, as there was uncertainty about the yield of organic crop production. In addition, customer use of traditional foods and fuels is expected to hamper the growth of the European white biotech market.

Impact of COVID-19 on Europe White Biotech Market

The Covid-19 pandemic had its adverse effect on almost all end-user verticals, in particular, the food & beverage sector. The shutdown of manufacturing units and disruption in supply chain due to the lockdown implemented in both developed and developing nations has declined the sales in the business, which is likely to continue for some time in future to gain complete consumer confidence.

This Research Report on Europe White Biotech Market is segmented and sub segmented into following categories

Europe White Biotech Market By Product

• Biochemical
• Industrial Enzymes
• Biofuels
• Biomaterials

Based on the products, the regional market is divided into biomaterials, biofuels, industrial enzymes, and biochemistry. Biofuels and biochemistry are the largest income generating segment. In 2017, these segments accounted for almost 70% of the white biotech business. Also, the volatile price of conventional fuels such as natural gas, natural oil and coal has created a potential opportunity for these segments.

Europe White Biotech Market By Product By Application

• Food
• Feed Additive
• Bioenergy
• Pharmaceutical Ingredients
• Personal Care and Household

The industry finds wide applications in food and feed additives, bioenergy, pharmaceutical ingredients, personal care and household products. Among these, bioenergy is expected to be the main application as it eliminates the adverse environmental effects of fossil fuels. Additionally, the pharmaceutical industry makes extensive use of white biotechnology to develop antibodies, active pharmaceutical ingredients (APIs), and other complex biomolecules. This segment is expected to capture more than 20% share of global market revenue throughout the study period.

Europe White Biotech Market By Region

• United Kingdom
• Germany
• France
• Italy
• Spain
• the rest of Europe

The Europe White Biotech market has been classified by geography into United Kingdom, Germany, France, Italy, Spain and the rest of Europe. Enzymes play a key role in ongoing efforts in Europe and the United States to harness and use biomass as a raw material for the production of high-value biofuels, biopolymers, and biochemicals from renewable resources. The increasing use of biomass is an efficient alternative to oil and is expected to have a positive impact on the environment, fuel economic growth and reduce the increased dependence on oil imports, which in turn should boost technology demand over the years of the forecast period. The healthy growth of the chemical industry has led to considerable demand for high-performance chemicals derived from renewable raw materials. This, in turn, has led to increased demand for biochemicals in Europe in recent years. The biochemicals segment is estimated to be the largest revenue-generating segment of the Europe white biotech market in the coming years, with a compound annual growth rate of 8.9% between 2016 and 2024.

KEY PLAYERS IN EUROPE WHITE BIOTECH MARKET

Key players in the Europe White Biotech Market include Novozymes, Cargill Inc., BASF SE, DuPont, and Archer Daniels Midland Company.

RECENT DEVELOPMENTS IN THE MARKET

• In May 2014, Kaneka signed a collaboration agreement with Terumo BCT Inc. to request clinical trials in the United States for its new LDL absorption system. Additionally, the Spectra Optia system can be found in hospitals across the United States, so, unlike the current situation, it will not be necessary to bring specialized devices or train hospital staff in the use of the device.
• Gilead has announced plans to acquire nearly half of the Pionyr anticancer biotechnology, with an exclusive option to acquire the rest of the company as the large pharmaceutical company continues to expand in oncology.
• Servier has signed a definitive agreement to acquire Symphogen A/S antibody discovery biotechnology. This acquisition, the result of a process that has been ongoing for several months, will strengthen Servier's antibody capabilities and ensure that the platform for development Symphogen early and antibody discovery are fully utilized.
• French pharmacist Sanofi agreed to buy Belgian biotech company Ablynx for € 3.9 billion ($ 4.8 billion), beating Novo Nordisk and achieving its second big deal this month after buying Bioverativ.
• TWB and Hamilton partnered to implement an innovative bioprocessing platform with 24 integrated mini-reactors (50 ml), which will greatly accelerate the process of developing industrial bioprocess solutions.
• White Biotech BRAIN AG has purchased specific gene-based industrial biotechnology assets from MerLion Pharmaceuticals GmbH.